Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bevacizumab biosimilar - AbbVie/Amgen

Next Previous
X
Search
Drug Profile

Bevacizumab biosimilar - AbbVie/Amgen

Alternative Names: ABP-215 (Mvasi); Bevacizumab-awwb; Mvasi

Latest Information Update: 03 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen; Watson Pharmaceuticals
  • Developer AbbVie; Amgen; Daiichi Sankyo Company
  • Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cervical cancer; Colorectal cancer; Glioblastoma; Non-small cell lung cancer; Renal cell carcinoma
  • Registered Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase I/II Brain metastases

Most Recent Events

  • 18 Oct 2023 Amgen and Criterium withdraws a phase-I/II trials in Brain metastases (Combination therapy, First-line therapy, Metastatic disease, Late-stage disease) in USA (IV), prior to enrolment (NCT05180422)
  • 06 Jan 2022 Criterium and Amgen plan a phase I/II trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Combination therapy, First-line therapy) (IV) (NCT05180422)
  • 21 May 2021 Amgen withdraws a phase III trial in Non-small cell lung cancer (Metastatic disease, Late stage disease, First-line therapy) in China prior to enrolment (NCT04466917)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top